Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Biotech Turnaround Fund (BTF)
investment firm
About
Biotech Turnaround Fund (BTF) B.V. is a cross-over, turnaround venture capital operating company, focusing on building a portfolio of six
- Bloemendaal,Noord-Holland,The Netherlands
- http://www.btf.eu
Highlights
Details
- Founded date
- Jan 1, 2000
- Operating Status
- Active
- Investor Type
- Venture Capital
Biotech Turnaround Fund (BTF) B.V. is a cross-over, turnaround venture capital operating company, focusing on building a portfolio of six late-stage biotechnology companies. Companies with several drug development candidates in phase II clinical trials.
Investments
Number of Investments
Number of Lead Investments
7
1
Biotech Turnaround Fund (BTF) has made 7 investments. Their most recent investment was on
Jan 1, 2008, when Genizon BioSciences raised $30.81M.
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Jan 1, 2008
Genizon BioSciences
|
Series E | $30.81M | Biotechnology | Yes |
|
Apr 19, 2007
CymaBay Therapeutics
|
Series D | $32M | Biopharma | — |
|
Feb 5, 2007
Genizon BioSciences
|
Series D | $10M | Biotechnology | — |
|
Aug 29, 2003
CymaBay Therapeutics
|
Series A | $27M | Biopharma | — |
|
Feb 25, 2003
Genizon BioSciences
|
Series Unknown | $7.70M | Biotechnology | — |
Exits
Biotech Turnaround Fund (BTF) has had 1 exits. Biotech Turnaround Fund (BTF) most notable exits include CymaBay Therapeutics
| Date | Company Name | Exit Type | Industry | |
|---|---|---|---|---|
| Jul 18, 2014 | CymaBay Therapeutics | IPO | Biopharma | Detail |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
